How is COVID-19 Pandemic Affecting Benign Prostatic Hyperplasia (BPH) Procedures?

Oct 28
20:08

2020

KumarPramod

KumarPramod

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

Benign Prostatic Hyperplasia (BPH) Procedures are expected to grow at a CAGR of 2.3% during 2017 – 2023, according to P&S Intelligence

mediaimage

Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care,How is COVID-19 Pandemic Affecting Benign Prostatic Hyperplasia (BPH) Procedures?  Articles since they are more prone to illness due to low immunity levels and longer recovery time. Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, prostate implants and laser based treatments. Thus, growing aging population acts as a strong driver supporting the increase in the number of BPH procedures performed.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-procedures/report-sample

According to the National Institute of Health, it has been estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than 80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH procedures.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-procedures/report-sample

Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe. France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH. 

NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.